Understanding the regulatory environment and processes from the OPV switch can support future time-sensitive vaccine introduction programs.
Answers are grounded in this paper and cite their sources.
Varied regulatory pathways for IPV and bOPV may hinder uniform global rollout; leaves open need for harmonized approval standards.
Withdrawal of type 2 oral poliovirus vaccine (OPV) in OPV-using countries required regulatory approval for use of inactivated poliovirus vaccine and bivalent OPV in routine immunization. Worldwide, a variety of mechanisms were used by member states, with some differences in approach observed between inactivated poliovirus vaccine and bivalent OPV. These included acceptance for use of World Health Organization (WHO) prequalified vaccines, registration and licensure pathways, participation in WHO-convened joint reviews of licensing dossiers, as well as pragmatic application of alternatively available mechanisms, when appropriate. Simple but effective tools were used to monitor progress and to record, authenticate, and share information. Essential to achievement of regulatory targets was ongoing communication with key stakeholders, including switch-country national regulatory authorities, vaccine manufacturers, partner organizations, and relevant units within WHO. Understanding of the regulatory environment gained through the OPV switch can be helpful in supporting further stages of the polio end game and other time-sensitive vaccine introduction programs.
No takes yet. Share an insight, caveat, or question.
Decina et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: